Baron and Budd Lists Qualifications for Participating in GranuFlo Lawsuit

  Baron and Budd Lists Qualifications for Participating in GranuFlo Lawsuit

 As lawsuits against the popular dialysis treatment progress, Baron and Budd
            provides information regarding lawsuit qualifications

Business Wire

DALLAS -- August 7, 2013

The popular dialysis drug GranuFlo has allegedly been linked to increased
risks of heart attack in patients. On March 29, 2012, the U.S. Food and Drug
Administration (FDA) issued a Class 1 recall of GranuFlo along with its sister
drug Naturalyte. According to the recall, “Inappropriate prescription of these
products can lead to a high serum bicarbonate level in patients undergoing
hemodialysis. This may contribute to metabolic alkalosis, which is a
significant risk factor associated with low blood pressure, hypokalemia,
hypoxemia, hypercapnia and cardiac arrhythmia, which, if not appropriately
treated, may culminate in cardiopulmonary arrest.”

To respond to these serious risks associated with GranuFlo use, many allegedly
injured patients have begun filing GranuFlo lawsuits to seek compensation for
their health complications. The national law firm of Baron and Budd has
responded by helping people understand the qualifications for a potential
GranuFlo lawsuit.

At this time, lawyers at Baron and Budd are encouraging patients who have
allegedly suffered serious injuries, such as heart attacks, while undergoing
dialysis to contact them for a free consultation. If you or someone you know
suffered from a heart attack after receiving dialysis, there is a possibility
that GranuFlo was used during the dialysis process and may be one of the
causes of your dangerous health issue.

While this Class 1 recall was initiated because of evidence that GranuFlo and
Naturalyte involve a risk of heart attack, cardiopulmonary arrest – even death
– during hemodialysis treatments, both GranuFlo and Naturalyte remain on the
market today. GranuFlo is manufactured by Fresenius Medical Care (FMC), the
world’s largest producer of all products and services related to dialysis;
over one-third of the 400,000 or more Americans who receive dialysis
treatments each year do so at Fresenius clinics where GranuFlo is often used.
In addition, GranuFlo is used in many dialysis clinics in non-Fresenius

If you or someone you know has received GranuFlo treatments during dialysis
and suffered serious health issues, contact our GranuFlo lawyers today at
1.866.855.4556 or email us at For more information about
GranuFlo lawyers and Baron and Budd, visit Baron and Budd’s website here:

For over 35 years, the lawyers at Baron and Budd have been protecting the
rights of people against negligent companies. The firm has an accomplished
track record of success when going up against large corporations such as
pharmaceutical companies. Baron and Budd lawyers were involved in the
litigation surrounding the diabetes drug Avandia, representing more than 7,000
patients harmed by Avandia use. Presently, Baron and Budd lawyers represent
numerous states in lawsuits against the manufacturer GlaxoSmithKline. In the
1990s, the firm was highly involved in the litigation surrounding then-popular
diet drug Fen-Phen, with a resulting global settlement valued at over $1.275

About Baron & Budd, P.C.

The law firm of Baron & Budd, P.C., with offices in Dallas, Baton Rouge,
Austin and Los Angeles, is a nationally recognized law firm with a 35-year
history of "Protecting What's Right" for people, communities and businesses
harmed by negligence. Baron & Budd's size and resources enable the firm to
take on large and complex cases. The firm represents individuals, governmental
and business entities in areas as diverse as water contamination, Gulf oil
spill, Qui Tam, California Proposition 65 violations, dangerous medications
and medical devices, Chinese drywall, insurance claims, consumer fraud,
securities fraud and asbestos-related illnesses such as mesothelioma.


Baron & Budd
Susan Knape, 214-629-0596
Amanda Billo, 214-991-1051